Prolifagen Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Prolifagen Therapeutics is pioneering a novel microRNA therapeutic approach, PRO302, designed to stimulate cardiomyocyte proliferation and regenerate heart muscle post-heart attack, moving beyond current standards of care that manage symptoms but do not repair damage. The company is led by a seasoned management team with deep experience in life sciences, cardiology, and company building. Operating in the massive and growing cardiovascular disease market, Prolifagen targets a transformative shift from disease management to true cardiac repair, though it faces the inherent risks of early-stage drug development and a complex competitive landscape.

Cardiovascular DiseaseMyocardial Infarction

Technology Platform

MicroRNA (miR) therapeutic platform designed to induce proliferation of cardiomyocytes to regenerate heart muscle tissue damaged after a heart attack.

Opportunities

The global burden of cardiovascular disease creates a multi-billion dollar market for a therapy that can genuinely repair heart muscle, moving beyond symptom management.

Success would establish a new treatment paradigm and could lead to a high-value acquisition or partnership with a major pharmaceutical company.

Risk Factors

The core scientific risk is unproven translation of microRNA-induced cardiomyocyte proliferation to safe and effective human therapy.

The company also faces significant regulatory uncertainty as a first-in-class regenerative approach and is dependent on raising substantial capital to advance its preclinical program.

Competitive Landscape

Competition includes large pharma with next-generation heart failure drugs (e.g., SGLT2 inhibitors) and other biotechs exploring cardiac regeneration via cell therapy, gene therapy, or different RNA mechanisms. Prolifagen's differentiation lies in its specific microRNA mechanism aimed directly at stimulating the heart's own cells to divide.

More companies in RNA Therapeutics (non-mRNA) →More companies in United States →